M. A. Pacciarini

4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study

Angelo Michele Carella, Gino Santini, Marina Martinengo et al. · Cancer · 1985 · 57 citations · Full text

Pilot Study, Hematological Malignancy, Oncology +15

A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors

Christophe Massard, Jean‐Charles Soria, Alan Anthoney et al. · Cell Cycle · 2011 · 53 citations

Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice.

M. A. Pacciarini, B Barbieri, Tina Colombo et al. · PubMed · 1978 · 50 citations

Antitumor Activity, Chemotherapeutic Effect, Therapeutic Activity +17

Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers.

A. C. Andreotti, E. Pianezzola, Stefano Persiani et al. · The Journal of Clinical Endocrinology & Metabolism · 1995 · 46 citations

Hypertension, Prl Secretion Areas, Pharmacological Study +11

Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses

S. Kaplan, Cristiana Sessa, Y Willems et al. · Investigational New Drugs · 1984 · 41 citations

Medicine, Antibiotic Adjuvant, Pharmacotherapy +5